KdT Ventures
kdtvc.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$100M
1 round on record
Latest round
$100M
Venture round · Oct 2024 · 23 mo ago
Backers
2
Clean Energy Ventures, Vintage Investment Partners
The money's age
Due for its next round
23 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 16, 2024
Raised a round Venture round $100M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2024 | $100M | — | wsj.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Clean Energy Ventures 
Vintage Investment Partners Similar startupsby what they do, their industry and backers
Investing to unlock systems change, faster than climate change.
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing™, a new biotechnology designed to offer scientists and…
A new era is here. From atom to mind. Founder & CEO @KernelCo. Also founder @OSFund & @Braintree / @venmo.
We seed early stage and highly innovative life sciences assets to create companies based on breakthrough assets.
Sacra is a research platform for private markets, angel and secondary investing. We provide research on pre-IPO, growth stage and…
Early Stage Startup that is Simplifying Business, One App at a Time.Forget about those overcomplicated, pricey software giants. We.
Overview
KdT Ventures is the standard for early-stage frontier science investing. Chemistry and biology are the software of our physical world; science is the source code of reality, from atoms to algorithms.
News
Shiprocket To Raise INR 219 Cr From KDT Ventures, Others
Logistics startup Shiprocket is raising INR 219 Cr in a funding round, which will be led by US-based venture capital (VC) firm KDT Ventures.
Read more
Report
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
media496481,496482
Read more
Report
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
KdT has formed a new company to develop NGM313 in a rare disease indicationNGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the ne
Read more
Report
KdT Ventures: Fund IV Closed At Over $100 Million
KdT Ventures announced the closing of its oversubscribed fourth fund (Fund IV), raising over $100 million to support early-stage, science-driven companies. And Fund IV is the firm's largest fund to date, and follows KdT's previous $80 million Fund III whi
Read more
Report
Financials
Total raised
$100M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $100M | Details |